PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit

Published on February 7, 2024

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds™" or the "Company"), a clinical-stage neuroscience company dedicated to the development of innovative therapies for neurological and neurodegenerative disorders, is thrilled to announce its selection as one of the prestigious presenters at the upcoming 2024 OBIO® Investment Summit.

The OBIO® Investment Summit, renowned for its focus on fostering growth and innovation in the healthcare sector, presents an ideal platform for PurMinds to showcase its cutting-edge research and development endeavors. This opportunity not only reflects the company's significant strides in neuroscience but also aligns perfectly with its mission to transform the landscape of neurotherapeutic treatments.

"We are honored to be selected to present at the 2024 OBIO® Investment Summit," said Janet Qi, CEO of PurMinds NeuroPharma. "This recognition is a testament to our team's dedication and the groundbreaking work we are doing. We look forward to sharing our vision with the global healthcare community and potential investors, and our Chief Scientific Officer, Dr. Alan Kozikowski, and Chief Innovation Officer, Dr. Amy Reichelt will be discussing our innovative pipeline focused on disease altering histone deacetylase inhibitors and serotonin-inspired neuroplastogens."

The OBIO® Investment Summit is set to take place on Feb 14 to 16, 2024, and it promises to be a convergence of some of the most innovative minds and companies in the healthcare industry. PurMinds NeuroPharma's participation underscores its commitment to leading the charge in developing novel therapies for those affected by neurological and neurodegenerative disorders.

For more information about PurMinds NeuroPharma and its participation in the OBIO® Investment Summit, please contact us by email at [email protected].


(Feed generated with FetchRSS)

 

Continue reading on website
Other news

Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta

February 6, 2024
Set the bar and then beat it; that's what Vertex Pharmaceuticals has just done with a next-gen cystic fibrosis (CF) treatment.The investigational treatment is a once-daily triple CFTR modulator regimen made up of vanzacaftor, tezacaftor and deutivacaftor, called vanza. This compares to Vertex’s own Trikafta (elexacaftor/tezacaftor/ivacaftor), the first triple combination therapy to snag FDA approv

Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors

February 7, 2024
SAN DIEGO and AUSTIN, Texas and HAMILTON, ON, Feb. 5, 2024 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the first patient has been dosed in its TACTIC-3 trial, a Phase I/II study, (NCT05862324) investigatin